Two things settle an appeal before any argument is made: who actually decided, and which instrument fits. A benefit manager issues determinations on behalf of a plan sponsor, so the challenge runs against the plan. And a formulary exception, a quantity override, a tier request, and a medical necessity appeal are different filings. Sending the wrong one burns the clock.
Medically reviewed by Dr. Shiv K. Goel, MD, FACP
The name on the letter is not always the decider
OptumRx administers pharmacy benefits under contract. The determination arrives on its letterhead because it operates the process, but the terms being applied were set by whoever bought the plan. For a self-funded employer, that employer is the party whose money pays claims and whose plan document governs. For a Medicare drug plan, the sponsoring plan carries the obligation under federal rules.
Establishing this early changes the strategy. If the refusal rests on a benefit the sponsor never purchased, the productive conversation is with the sponsor’s benefits team, not with the administrator applying the purchase. If the refusal rests on criteria not being met, the administrator’s process is exactly the right venue.
Pick the instrument that matches the reason
| Instrument | What it asks for | When it fits |
|---|---|---|
| Formulary exception | Cover a product absent from the plan’s list | The drug is off list or on an exclusion list |
| Tier or cost-share exception | Charge the member at a lower cost-share level | The drug is covered but expensive to the member |
| Quantity limit override | Permit more than the standard fill allows | The regimen exceeds a supply rule |
| Medical necessity appeal | Reverse a criteria decision on clinical grounds | A review was completed and refused |
| Benefit interpretation dispute | Confirm what the plan document actually covers | The dispute is about scope, not medicine |
Get the record before writing anything
Three documents decide whether an appeal is worth filing. The written determination, which names the requirement that was not satisfied. The criteria document the decision was applied against. And the plan’s summary description, which states whether the category was purchased at all. Members are generally entitled to the standard used to decide their case, and asking in writing produces a sharper answer than a phone call.
Reading those three together resolves most cases without argument. A refusal citing a category exclusion and a refusal citing missing documentation look similar on paper and require opposite responses.
The criteria document is the piece people skip, and it is the one that decides outcomes. It states in plain terms what a reviewer had to see. An appeal written against that text, point by point, behaves very differently from one written against a general sense of unfairness, because the reviewer at the next stage is reading the same document.
Exclusions and criteria failures are not the same fight
A category exclusion is a purchasing outcome. The sponsor did not buy coverage for anti-obesity medication, and clinical evidence does not change what was bought. These appeals fail at very high rates for structural reasons, and the honest advice is to redirect the effort toward the sponsor’s benefits committee at the next renewal, or toward cash pricing now.
A criteria failure is different. Something specific was missing or mismatched, and supplying it can flip the answer without any change to the plan. That is a solvable problem and worth real effort.
Which indication is being appealed
Zepbound carries two approved indications: long-term weight reduction and maintenance, and moderate to severe obstructive sleep apnea in adults with obesity. If a plan excludes weight-management drugs as a category but the patient has a documented sleep apnea diagnosis, the appeal is arguing a different question against a different part of the benefit. Sleep medicine records, including diagnostic testing, become the relevant evidence rather than weight history. Stating clearly which indication is at issue prevents the file being reviewed against the wrong standard a second time.
Providers that sell outside the benefit often spell out which indication they treat, which helps a patient anticipate the same distinction an appeal has to draw. HealthRX describes its Zepbound prescribing on a public page, and Henry Meds, LillyDirect, and NovoCare each post their own terms. None of them decides a plan’s answer, but reading a few clarifies what the cash market looks like if the weight-management route stays closed.
Medicare drug plans follow a separate track
Part D operates under a federally defined sequence beginning with a coverage determination request and moving through named review stages with their own deadlines. Commercial group coverage instead runs an internal review followed, in most cases, by an independent external review. The two systems use overlapping vocabulary for different things, so guidance written for one route can mislead someone on the other.
Keep a parallel path open
Appeals take weeks even when they succeed, and treatment plans rarely tolerate an open-ended pause. Pricing the alternatives while the file moves means a refusal changes the cost rather than stopping everything. Manufacturer self-pay pharmacies post their figures, and clinician-supervised cash services publish flat monthly rates. FormBlends is one such service, alongside Ro, Hims and Hers, and a range of independent weight-management clinics. Compounded preparations sold through those routes are made by compounding pharmacies and are not FDA-approved products, which is a material difference from the branded injection an appeal is trying to secure.
Frequently asked questions
Should the appeal be addressed to the benefit manager or the employer?
It depends on the reason. Criteria decisions are handled through the administrator’s published process. Disputes about whether the category was purchased belong with the employer’s benefits team, since the plan document and the money behind it are theirs, not the administrator’s.
What evidence moves a criteria decision?
Dated clinical records that speak directly to the requirement named in the refusal. Chart notes, measurements, diagnostic reports, and a clear account of what was tried and what happened. Statements of preference carry no weight. Precision against the cited requirement matters more than volume.
Can an appeal be filed for a drug the plan excludes outright?
It can be filed, and it will usually fail. Exclusions are contractual rather than clinical, so the review has no discretion to grant something the plan never covered. Effort is generally better spent on the next plan year or on cash pricing.
Does a sleep apnea diagnosis create a separate route?
Potentially. It is a separate approved indication with its own evidence base, and some plans handle it under different terms from weight management. It is not automatic, and it depends entirely on how the specific plan defines its exclusions and its covered categories.
How many attempts are reasonable?
Usually one well-built internal appeal, followed by external review if the reason was clinical. Repeating an identical submission changes nothing. If the second refusal repeats the same contractual language, that is the signal to stop appealing and start planning around the cost.
